210 related articles for article (PubMed ID: 9923820)
1. Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines.
Kalemkerian GP; Ou X
Cancer Chemother Pharmacol; 1999; 43(2):145-50. PubMed ID: 9923820
[TBL] [Abstract][Full Text] [Related]
2. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines.
Kalemkerian GP; Slusher R; Ramalingam S; Gadgeel S; Mabry M
J Natl Cancer Inst; 1995 Nov; 87(22):1674-80. PubMed ID: 7473815
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
5. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy?
Ohlmann CH; Jung C; Jaques G
Int J Cancer; 2002 Aug; 100(5):520-6. PubMed ID: 12124800
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
7. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
8. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin for small-cell lung cancer.
Aisner J; Abrams J
Semin Oncol; 1989 Aug; 16(4 Suppl 6):2-9. PubMed ID: 2548282
[TBL] [Abstract][Full Text] [Related]
10. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions.
Bunn PA
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-153-S12-162. PubMed ID: 9331142
[TBL] [Abstract][Full Text] [Related]
11. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines.
Zou CP; Kurie JM; Lotan D; Zou CC; Hong WK; Lotan R
Clin Cancer Res; 1998 May; 4(5):1345-55. PubMed ID: 9607596
[TBL] [Abstract][Full Text] [Related]
12. Concurrent paclitaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer.
Ettinger DS
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):148-50. PubMed ID: 10210554
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of magainin analogues against human lung cancer cell lines.
Ohsaki Y; Gazdar AF; Chen HC; Johnson BE
Cancer Res; 1992 Jul; 52(13):3534-8. PubMed ID: 1319823
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V
Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Kaposi's sarcoma in vivo by fenretinide.
Ferrari N; Morini M; Pfeffer U; Minghelli S; Noonan DM; Albini A
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6020-9. PubMed ID: 14676128
[TBL] [Abstract][Full Text] [Related]
16. Combinations of paclitaxel and etoposide in the treatment of lung cancer.
Perez EA; Buckwalter CA; Reid JP
Semin Oncol; 1996 Dec; 23(6 Suppl 15):21-5. PubMed ID: 8996593
[TBL] [Abstract][Full Text] [Related]
17. The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
Bunn PA
Semin Oncol; 1996 Dec; 23(6 Suppl 16):18-25. PubMed ID: 9007116
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
Lu C; Komaki R; Lee JS; Shin DM; Palmer JL; Coldman BJ; Pisters KM; Kurie JM; Fossella FV; Glisson BS
Clin Cancer Res; 2003 Jun; 9(6):2085-91. PubMed ID: 12796372
[TBL] [Abstract][Full Text] [Related]
19. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification.
Kalemkerian GP; Ou X; Adil MR; Rosati R; Khoulani MM; Madan SK; Pettit GR
Cancer Chemother Pharmacol; 1999; 43(6):507-15. PubMed ID: 10321512
[TBL] [Abstract][Full Text] [Related]
20. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
